Author Correction: Integration of whole-body [18F]FDG PET/MRI with non-targeted metabolomics can provide new insights on tissue-specific insulin resistance in type 2 diabetes

• Klev Diamanti,
• Robin Visvanathar,
• Maria J. Pereira,
• Marco Cavalli,
• Gang Pan,
• Chanchal Kumar,
• Stanko Skrtic,
• Ulf Risérus,
• Jan W. Eriksson,
• Joel Kullberg,
• Jan Komorowski,
• Claes Wadelius,
• Håkan Ahlström

Affiliations

Klev Diamanti

Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University

Robin Visvanathar

Department of Surgical Sciences, Section of Radiology, Uppsala University

Maria J. Pereira

Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University

Marco Cavalli

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University

Gang Pan

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University

Chanchal Kumar

Translational Science & Experimental Medicine, Research and Early Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca

Stanko Skrtic

Pharmaceutical Technology & Development, AstraZeneca AB

Ulf Risérus

Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University

Jan W. Eriksson

Department of Medical Sciences, Clinical Diabetes and Metabolism, Uppsala University

Joel Kullberg

Department of Surgical Sciences, Section of Radiology, Uppsala University

Jan Komorowski

Science for Life Laboratory, Department of Cell and Molecular Biology, Uppsala University

Claes Wadelius

Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University

Håkan Ahlström

Department of Surgical Sciences, Section of Radiology, Uppsala University